Delivery Order SPE2DB22D2006-SPE2DB25FW4AB
Award Date 9/4/25
Potential Completion Date 9/5/25
Potential Value $79K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $14,708.04 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on September 3, 2025, with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic inflammatory...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes valued at $2,022.79 on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $37,709.53. This is a firm fixed price delivery order with an ultimate completion date of August 25, 2025, to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a contract value of $42,767.05. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $33,470.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to...
- The Defense Logistics Agency awarded a $26,083.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The contract will be...